The global interventional cardiology market is projected to reach $30 billion by 2027, with the CTO segment representing a rapidly growing segment. With 50,000+ CTO PCI procedures performed in the United States, an estimated 180,000+ bypass surgeries occurring involving a CTO, and over 200,000 CTO patients medically managed, this device can access a $1.6 billion target addressable market opportunity. 

The number of bypass surgeries that still occur in the United States highlights the significant unmet need for more effective and efficient solutions, which the TigerheartTM addresses. In addition to the large addressable market, established reimbursement codes for both the treatment of coronary CTOs and for diagnostic imaging already exist.